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Aldosterone has pro-fibrotic properties and is a potential
target for additional intervention in patients with chronic
renal disease showing resistance to therapy during treatment
with angiotensin-converting enzyme inhibitors (ACEi).
Combining ACEi and aldosterone receptor blockade (aldoRB)
in proteinuric renal disease reduces proteinuria, but effects
on proteinuria-induced renal damage are unknown. We
studied the effect of ACEi/aldoRB in adriamycin nephrosis
(AN). Six weeks after injection of adriamycin in Wistar rats,
randomized treatment with vehicle (VEH, n¼ 8), aldoRB
(n¼ 12), ACEi (n¼ 10), or a combination of ACEi/aldoRB
(n¼ 14) was given for 12 weeks. Healthy rats served as
controls (n¼ 6). Renal damage was quantified by markers of
tubular injury (osteopontin (OPN) and kidney injury
molecule-1 (Kim-1)), pre-fibrotic lesions (a-smooth muscle
actin (SMA)), interstitial fibrosis (IF), and focal
glomerulosclerosis (FGS). In AN animals, proteinuria was
increased compared with controls. ACEi and ACEi/aldoRB
significantly reduced proteinuria compared with VEH,
whereas aldoRB monotherapy was without effect. Blood
pressure was reduced in ACEi and ACEi/aldoRB compared
with VEH and aldoRB. OPN and Kim-1 were increased in AN
animals, but significantly reduced by ACEi/aldoRB. Treatment
with ACEi and ACEi/aldoRB prevented an increase of SMA,
IF, and FGS. In conclusion, ACEi/aldoRB effectively
reduced proteinuria and markers of tubular injury and
prevented renal damage in this rat model of chronic
proteinuria-induced renal damage.
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Blockade of the renin–angiotensin–aldosterone system
(RAAS) is currently the first choice of therapy for chronic
renal disease. However, in some patients, RAAS blockade by
angiotensin-converting enzyme inhibition (ACEi) or angio-
tensin II type 1 antagonists as such is not sufficiently effective
in reducing proteinuria. This resistance to therapy results in
ongoing renal function loss and, consequently, a growing
incidence of patients with end-stage renal disease.1,2 This
resistance to therapy can be overcome in part by the
combination of ACEi and angiotensin II type 1 antagonists
or by adding diuretics or a low-sodium diet to RAAS
blockade. These combination strategies aim at preventing the
fibrotic actions of angiotensin II. However, angiotensin II is
not the only effector hormone of the RAAS. The miner-
alocorticoid hormone aldosterone, which is stimulated by
angiotensin II, is involved in sodium and potassium home-
ostasis, but has profibrotic properties as well.3,4 Although
ACEi can reduce aldosterone, however, the suppression is not
complete, especially during low-sodium intake,5 and in the
long-term ACEi aldosterone escape may contribute resistance
to therapy.6
In experimental models of hypertensive renal damage,
aldosterone receptor blockade (aldoRB) reduces glomerulo-
sclerosis and proteinuria, supporting the importance of
aldosterone in renal damage.7–9 Not only hypertension is
important in chronic progressive renal function loss, but also
proteinuria is crucially involved. However, no data are
available so far in models of proteinuria-induced renal
damage. Studies in proteinuric patients showed that addition
of the aldoRB spironolactone (SPIR) to an ACEi could
further reduce proteinuria.10–12 However, these were short-
term studies and no data on renal structural damage are
available.
Therefore, we studied the effect of combining ACEi
(lisinopril (LIS)) and aldoRB (SPIR) in adriamycin nephrosis
(AN), an experimental model of chronic proteinuria-induced
renal damage on clinical parameters and on renal damage,
such as tubular injury (osteopontin (OPN) and kidney injury
molecule-1 (Kim-1)), interstitial pre-fibrotic changes
(macrophage influx, a-smooth muscle actin (SMA)), inter-
stitial fibrosis (IF), and focal glomerulosclerosis (FGS).
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RESULTS
Clinical parameters (Table 1)
The time course of proteinuria and blood pressure are shown
in Figure 1. Six weeks after induction of nephrosis, mean
proteinuria was 2147125 mg/24 h. In vehicle rats, proteinuria
progressed to 6417287 mg/24 h at week 18. Treatment
with monotherapy SPIR did not reduce proteinuria
(5697284 mg/24 h), whereas LIS (2897218 mg/24 h) and
the combination of LIS/SPIR (1877190 mg/24 h) signifi-
cantly reduced proteinuria compared with VEH animals and
with SPIR alone. However, there was no significant difference
between the LIS and LIS/SPIR groups in proteinuria and
blood pressure, either when analyzed for the separate time
points or for the mean of all values during the active
treatment period. There was a linear trend in proteinuria,
with the highest values in vehicle and lowest in controls
(Po0.01 for trend). LIS and LIS/SPIR reduced blood
pressure (118725 and 101725 mm Hg, respectively) com-
pared with VEH animals (169733 mm Hg) (both Po0.05),
whereas SPIR monotherapy was without effect. Blood
pressure was also significantly reduced in the combination
group compared with healthy controls (controls:
13778 mm Hg). Blood pressure also showed a linear trend
with highest values in vehicle and lowest in LIS/SPIR
(Po0.01 for trend), both for the values at the separate time
points and the mean of all values during treatment.
Serum creatinine did not differ between the various
groups; however, urea was increased in the combination
group compared with vehicles, reflecting the volume deple-
tion by LIS/SPIR. Plasma potassium was not increased in the
LIS/SPIR group compared with the vehicle-, SPIR-, and LIS-
treated groups, and thus the combination of LIS/SPIR in this
study did not induce hyperkalemia. Water intake, and
therefore drug intake, of LIS was comparable in all groups.
Markers of tubular injury (OPN and Kim-1)
OPN mRNA. In all AN animals, OPN mRNA was increased
compared with healthy controls (Po0.05). Monotherapy
with SPIR or LIS did not significantly reduce the amount of
OPN mRNA compared with vehicle, although there was a
stepwise numerical reduction. Only the combination of LIS/
SPIR significantly reduced the amount of OPN mRNA
induction compared with vehicle (Figure 2a).
OPN protein. Healthy control animals showed virtually no
cortical OPN protein expression. As anticipated, OPN was
present in the medulla and collecting ducts of these animals.
In adriamycin animals, OPN was found in the cytoplasm of
injured and dilated tubules, medulla, and collecting ducts.
However, treatment with SPIR or LIS numerically reduced
cortical interstitial OPN staining, without reaching statistical
significance. Only the combination of LIS/SPIR significantly
reduced cortical OPN expression compared with vehicle
animals (Figures 2b and 3a–g).
Kim-1 mRNA. Kim-1 mRNA, which is induced in injured
proximal tubules, was significantly induced in all adriamycin
animals compared with healthy controls. None of the
Table 1 | Clinical parameters
VEH (n=8) SPIR (n=12) LIS (n=10) LIS/SPIR (n=14) CON (n=6)
Body weight (g) 474728 455728 451728 464730 504752
Water intake (ml/day) 1376 1274 2277& 2476*,& 1579
Urinary volume (ml/day) 1876 1476 2476& 2479& 16710
Serum creatinine (mmol/l) 69713 67715 65711 69713 5572
Creatinine clearance (ml/min) 2.070.5 1.770.6 1.770.3 1.770.4 1.470.4
Serum urea (mmol/l) 8.872.7 10.474.9 11.273.7 16.675.7* 6.570.4
Serum potassium (mmol/l) 6.070.3# 5.670.5# 6.270.4#,&,@ 5.770.4# 4.570.3
Serum sodium (mmol/l) 14975 14377 13875 13975 13772
CON, control; LIS, lisinopril; SPIR, spironolactone; VEH, vehicle-treated.
xPo0.05 vs CON, *Po0.05 vs VEH, &Po0.05 vs SPIR, @Po0.05 vs LIS/SPIR.
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Figure 1 | Blood pressure and proteinuria in the different
treatment groups. (a) Blood pressure measured by tail cuff
plethysmography, (b) Proteinuria in the different adriamycin groups
and healthy controls. Both graphs represent mean and s.e.m.
VEH: vehicle-treated; SPIR, spironolactone-treated; LIS, lisinopril-
treated; LIS/SPIR, combination of LIS and SPIR; CON, healthy
control rats.
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treatments reduced the expression of Kim-1 mRNA, although
a stepwise decrease in Kim-1 mRNA from vehicle downwards
to LIS/SPIR was apparent (Figure 2c).
Kim-1 protein. In healthy control animals, no renal Kim-1
protein expression was detected. However, Kim-1 was
significantly induced in VEH adriamycin animals compared
with controls. A numerical, but not statistically significant,
reduction of Kim-1 was observed in SPIR- and LIS-treated
groups. However, a significant reduction was found in
the LIS/SPIR-treated rats compared with the VEH rats
(Figures 2d and 3f–j).
The induction of OPN and Kim-1 mRNA showed a strong
parallel with proteinuria across the groups (Kim-1 with
proteinuria R2¼ 0.63, Po0.001; OPN with proteinuria
R2¼ 0.61, Po0.001). For higher levels of proteinuria, more
tubular damage is present. Also, the expressions of OPN and
Kim-1 were strongly associated with each other (R2¼ 0.81,
Po0.001).
Glomerular and interstitial inflammation, pre-fibrotic
changes, and structural damage
Macrophages. Influx of peritubular interstitial macro-
phages was very low in healthy control animals, whereas in all
adriamycin animals macrophage influx was increased.
Treatment with SPIR, LIS, or LIS/SPIR numerically reduced
interstitial macrophage influx (Figure 4a). Glomerular
macrophages were comparable in all groups, with 1.371.2
macrophages/glomerulus in the vehicle group, 0.770.5 in the
SPIR group, 1.570.5 in the LIS group, 1.070.9 in the LIS/
SPIR group, and 1.070.4 macrophages/glomerulus in the
healthy controls. No significant differences were found.
a-SMA. In healthy control animals, a-SMA was present
only in the vessel wall of intrarenal arteries. In adriamycin
animals, a-SMA expression was found in arteries and in the
interstitial space surrounding dilated tubules. In VEH- and
SPIR-treated animals, interstitial a-SMA was increased
compared with controls. In LIS- and LIS/SPIR-treated rats,
a-SMA was significantly reduced compared with vehicle, and
values were comparable to healthy controls (Figure 4b).
Collagen type IV. In all groups, collagen IV (cIV)
deposition was observed surrounding all tubular basement
membranes. Collagen deposition was significantly increased
in the vehicle group compared with healthy controls.
Treatment with LIS or LIS/SPIR reduced cIV deposition
compared with VEH animals, and LIS/SPIR also reduced cIV
compared with SPIR-treated animals (Figure 4d).
FGS and IF. There was a significant increase in FGS and IF
in all adriamycin animals compared with controls, with
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Figure 2 | Markers of tubular damage at termination; graphs
represent mean and SD. (a) OPN mRNA (qPCR), (b) OPN protein
expression (computer-assisted morphometry), (c) Kim-1 mRNA
(qPCR), and (d) Kim-1 protein expression (computer-assisted
morphometry). Mean and SD are given.
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Figure 3 | Photomicrographs of OPN and Kim-1
immunohistochemistry (brown) with PAS counterstaining.
Left panel: OPN immunohistochemistry. Right panel: Kim-1
immunohistochemistry. (a, b) VEH animals, (c, d) SPIR-treated
animals, (e, f) LIS-treated animals, (g, h) LIS/SPIR-treated animals, and
(I, j) healthy controls. In VEH, OPN and Kim-1 are abundantly present,
during treatment OPN and Kim-1 staining decreases. In controls,
no OPN and Kim-1 staining is present in the cortex.
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highest values in the vehicle group, followed by SPIR, LIS,
and with lowest scores in the LIS/SPIR group (Po0.01 for
trend). IF was significantly reduced in the LIS/SPIR group
compared with the SPIR group (Po0.05; Figure 4e). FGS was
reduced in the LIS/SPIR group compared with the vehicle
and SPIR groups (Po0.05; Figure 4f). Photomicrographs of
FGS in the different treatment groups are shown in Figure 5.
Correlation between renal damage and proteinuria. In line
with the parallel between proteinuria and markers of tubular
injury in figure 4, a strong association exists also for the other
markers of renal damage. When all animals (treated and
untreated) are taken together, proteinuria shows the follow-
ing Spearman’s r coefficients at week 18 with markers of
renal damage: macrophages r¼ 0.73, a-SMA r¼ 0.84, cIV
r¼ 0.50, IF r¼ 0.77, and FGS r¼ 0.83; all Po0.001.
DISCUSSION
In this experiment on proteinuria-induced renal damage, we
demonstrate that combining an ACEi with an aldoRB is
effective in reducing proteinuria and blood pressure. To our
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Figure 4 | Interstitial and glomerular damage at termination; graphs represent mean and s.d. (a) Macrophages per interstitial field,
(b) a-SMA expression (computer-assisted morphometry), (c) transforming growth factor b1 mRNA (real-time PCR) in cortical tissue (fold
induction 103), (d) cIV expression (computer-assisted morphometry), (e) IF, semiquantitative score (arbitrary units, 0–400), and (f) FGS,
semiquantitative score (arbitrary units, 0–400).
Figure 5 | Detailed photomicrographs of FGS in the different treatment groups.
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knowledge, this is the first study that combines these two
regimens in animals with proteinuria-induced renal damage
to study the effects on renal damage. Our data on the clinical
parameters are in line with reports in proteinuric patients,
where the addition of aldoRB to ACEi treatment led to a
further reduction of proteinuria.11–13 Furthermore, we noted
a remarkable reduction of FGS and tubulo-interstitial
damage in the combination group, providing further
evidence for the beneficial effect of this treatment regimen.
The beneficial effect of combining ACEi and aldoRB has
been demonstrated in radiation injury and hypertensive
injury in rats.9,14 In line with these studies, ACEi and ACEi/
aldoRB in our study showed a strong reduction of
proteinuria compared with untreated animals. Monotherapy
with aldoRB, on the other hand, did not reduce proteinuria,
which was also seen in other studies.15,16 An important
difference of our study, compared with other studies, is the
timing of the onset of treatment. We used a curative setting,
investigating the efficacy of intervention started at a time
when proteinuria is well established and when early lesions
are already present, whereas others only studied the
combination of ACEi and aldoRB in a preventive setting,
namely starting treatment together with the induction of
disease. Our curative setting more closely resembles the
clinical situation where patients usually come under medical
attention after proteinuria has been present for some time
already. Delayed-onset treatment has been used in a
hypertensive rat model to compare losartan, eplerenone,
and placebo for cardiac and renal damage,17 where treatment
was started either at disease induction or 4 weeks thereafter.
No differences in renal damage were present between the
different treatment regimens, either for the timing of
treatment or between losartan and eplerenone. Proteinuria
was only prevented when treatment was started at disease
induction, whereas in our study, proteinuria and tubular
damage were reduced and the development of structural
damage was prevented with a delayed start of treatment with
ACEi and ACEiþ aldoRB.
However, our study has some limitations. Volume
depletion is known to enhance the effect of ACEi on blood
pressure and proteinuria,18 both when obtained by diuretic
and by low sodium intake,19 and could thus account for the
effects in the ACEi/aldoRB group. The data presented here do
not allow to discriminate whether the effective reduction of
proteinuria and renal damage in our ACEi/aldoRB group is
due to indirect effects by the diuretic effect of SPIR or due to
specific antifibrotic properties. In our original study design, a
control group using LIS plus the potassium-sparing diuretic
amiloride was included to control the effects of SPIR on
volume and potassium status. Unfortunately, our nephrotic
rats did not tolerate the amiloride regimen – although similar
doses have successfully been used in various conditions in
rats;20,21 so we were unable to dissect the effects of possible
diuretic actions of SPIR. Nevertheless, close consideration of
recent data on the renal structural effects of ACEi combined
with volume depletion in the adriamycin model reveals a
remarkable contrast with the current data. The combination
of ACEi plus low sodium, as compared with ACEi during
normal sodium status, in an experimental design similar to
the current study, led to an additional effect on blood
pressure, proteinuria, and glomerular damage without,
however, beneficial effects on interstitial damage. By contrast,
interstitial damage was aggravated by the volume depletion
during ACEi.22 These findings were consistent with another
recent study in our lab, with serial renal biopsies in
adriamycin rats, showing progression of interstitial damage
during the combination of ACEi plus volume depletion by
low sodium, inspite of reduction of blood pressure and
proteinuria and stabilization of FGS.23 Thus, the effects of
ACEi plus SPIR are concordant with those of ACEi plus low
sodium for blood pressure, proteinuria, and glomerular
lesions, but dissociate for tubulo-interstitial damage, as the
latter is improved by ACEi plus SPIR, but worsens during
ACEi plus low sodium. In our opinion, this renders it
unlikely that the beneficial tubulo-interstitial effect of the
combination of ACEi plus SPIR in the current study is
explained by an effect of SPIR on volume status. Further
studies are needed to explore this issue in more detail and to
address the underlying molecular mechanisms. Moreover, it
would be of interest to address the specific aldosterone
antagonist eplerenone for its effectiveness in combination
with ACEi on proteinuria-induced renal damage. Another
limitation might be the dose of SPIR. The dose was based on
earlier studies. However, owing to higher body weight of our
animals, the dosing of SPIR is slightly below the dose that
inhibits 95% of the aldosterone binding in vivo, but far above
the dose that inhibits 60% of the aldosterone binding.24 At
any rate, the efficacy of the combination with ACEi supports
the pharmacological efficacy of the current dose, although it
did not lead to significant clinical responses as a mono-
therapy.
The combination of ACEi and aldoRB effectively reduced
markers of tubular damage compared with untreated
animals, and prevented the interstitial and glomerular
damage that developed in the SPIR and VEH animals. The
therapeutic effect on renal damage can be due to the
reduction of proteinuria by this regimen, which is supported
by the strong correlation between proteinuria and all markers
of renal structural damage. The therapeutic effect could also
be due to the antifibrotic effect of SPIR, which has been
suggested to exert its effect through a reduction in
transforming growth factor-b levels.25 In the current study,
however, we could not substantiate an effect on transforming
growth factor-b expression. Blockade of the mineralocorti-
coid receptor and reduced angiotensin II levels (by ACEi)
may have direct effects on OPN, as earlier studies showed in
vivo and in vitro induction of OPN after treatment with
aldosterone.26–29 Reduction of markers of tubular damage,
such as OPN and Kim-1, by ACEi/aldoRB, as observed here,
is in line with those studies. Whether such a reduction, in
itself, could play a role of the mechanism of prevention of
(pro)fibrotic lesions, such as expression of a-SMA and
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increased cIV deposition, cannot be derived with certainty
from our study and should be the subject of further study.
In conclusion, combination of aldoRB and ACEi reduced
proteinuria, blood pressure, and tubular damage and
prevented the development of IF and FGS in a rat model of
proteinuria-induced renal damage. Further studies are
needed to investigate the precise mechanisms underlying
these protective effects. These data support a potential role
for adjunct aldoRB in proteinuric patients treated by RAAS
blockade, but long-term clinical trials are needed to
substantiate this assumption.
MATERIALS AND METHODS
Animals
Fifty male Wistar rats (HsdCpb: Wu; Harlan Inc., Zeist, The
Netherlands) weighing 250–275 g were used. All experimental
procedures were approved by the Committee for Animal Experi-
ments of the University of Groningen. The animals were housed in a
temperature-controlled room with a 12 h light–dark cycle. Animals
were allowed 1 week to adjust after arrival and had free access to
food and water during the entire study. All surgical procedures took
place under isoflurane anesthesia in N2O/oxygen (1:2).
Experimental design
AN was induced by injection of 1.75 mg/kg adriamycin (Doxor-
ubicins) into the tail vein (n¼ 44). After 6 weeks, rats were
stratified according to proteinuria into four groups and received
treatment for 12 weeks. The first group was a vehicle group,
receiving normal drinking water (VEH, n¼ 8). The second group
was treated with the aldosterone receptor blocker SPIR (n¼ 12). The
third group received the ACEi LIS (n¼ 10). The fourth group
received a combination of ACEi and aldoRB LIS/SPIR (n¼ 14).
Healthy rats that did not receive adriamycin injection served as time
controls (n¼ 6). SPIR was provided by a 60-day slow-release
subcutaneous pellet (Innovative Research of America, Sarasota, FL,
USA) at a dose of 3.3 mg/day. The pellet was placed in the lateral
side of the neck in a pocket made with an incision and forceps.
After 8 weeks (at week 14), a second pellet was placed for the
remaining 4 weeks; average dosing of SPIR was 8 mg/kg/day. LIS was
provided in drinking water (75 mg/l Merck & Co, Rahway, NJ,
USA), average LIS intake was 5 mg/kg/day. At the end of the study,
blood was collected by cannulation of the abdominal aorta, and
kidneys were perfused in situ with saline and removed. From the left
kidney, two sections were snap-frozen in liquid nitrogen and stored
at 801C for molecular analysis. From the right kidney, one slice
was fixed in 4% paraformaldehyde and another was fixed in
methacarn.
In addition to these groups, an additional group (n¼ 14), also
stratified for proteinuria, was treated with LIS (75 mg/l in drinking
water) plus amiloride to control for the possible diuretic effects of
SPIR. Amiloride was chosen as a control potassium-sparing diuretic
that has no effects on aldosterone. Amiloride was given in
subcutaneous pellets (Innovative Research of America, Sarasota,
FL, USA, 200 mg, 90-day release, 2.2 mg/day). Previous experiments
with amiloride showed antihypertensive effects at 7.5 mg/kg/day20 or
even at 20 mg/kg.21 Within 1 week after implantation, these animals
lost more than 10% of their initial bodyweight, even after switching
to normal drinking water, that is, withdrawal of LIS. Some of the
rats died. According to the regulations of the Committee for Animal
experiments, the other animals were killed because of more than
10% weight loss. Because of premature death, no outcome data are
available for these rats.
Clinical parameters
During the study, systolic blood pressure was measured weekly in
trained conscious rats using tail-cuff plethysmography (Apollo 179,
IITC Life Science, Woodland Hills, CA, USA). Urine (24 h) was
collected 2-weekly in metabolic cages with measurement of food and
water intake. Urinary protein excretion was measured by the
pyrogallol red molybdate method.30 Serum and urine concentra-
tions of creatinine, urea, sodium, and potassium were all analyzed
on a multi-test analyzer system (Merck Mega, Darmstadt, Germany)
with Ecolines MEGA reagents (Diasys Diagnostic Systems,
Holzheim, Germany). Creatinine concentrations in urine and
serum were determined with the Jaffe´ method. Serum values of
urea were determined with the urease-GLDH method and
concentrations of potassium and sodium were measured with
indirect potentiometry.
RNA isolation and quantitative polymerase chain
reaction (qPCR)
Quantitative polymerase chain reaction (qPCR) analysis based on
the TaqMan methodology was performed using an ABI Prism 7900
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). Sequences of the primers and probe for glyceraldehyde-3-
phosphate dehydrogenase mRNA were as follows: forward: 50-GAA
CAT CAT CCC TGC ATC CA-30; reverse: 50-CCA GTG AGC TTC
CCG TTC A-30; probe: 50-CTT GCC CAC AGC CTT GGC AGC-30.
The Taqman probes were labelled at the 50 end with a reporter
fluorochrome (FAM) and at the 30 end with a quencher
fluorochrome (TAMRA). OPN, Kim-1, and transforming growth
factor b1 gene-specific Taqman probe and primer sets were obtained
from Applied Biosystems as assays-on-demand gene expression
products. The assays-on-demand identities were as follows: OPN
(Spp1), Rn 00563571 m1; Kim-1, Rn 00597703 m1; and transform-
ing growth factor-b1, Rn 00572010 m1.
Total RNA was extracted using the Trizol method (Invitrogen,
Carlsbad, CA, USA). DNAse treatment was performed using Turbo
DNA-free (Ambion, Austin, TX, USA). cDNA was synthesized from
200 ng of total cellular RNA by First Strand cDNA Synthesis System
and Superscript II Rt (Invitrogen) using random hexamers in a
volume of 20 ml and further diluted to a concentration of 2 ng/ml.
The qPCR reaction mixture contained 5 ml cDNA and 10 ml
2TaqMan Universal PCR Master Mix (Eurogentec, Seraing,
Belgium). For glyceraldehyde-3-phosphate dehydrogenase,
900 nmol/l of each primer and 200 nmol/l probe in a total reaction
volume of 20 ml were added. For OPN and Kim-1, 1 ml 20 assays-
on-demand gene expression assay mix was added to the 5 ml cDNA
and 10 ml mastermix; nuclease-free water was added to get a total
reaction volume of 20ml. All assays were performed in triplicate.
Reaction tubes without template cDNA served as negative controls.
The PCR plate was incubated for 2 min at 501C and 10 min at 951C,
followed by 40 cycles of 15 s at 951C and 1 min at 601C. The CT
(threshold cycle) is inversely proportional to the logarithmic scale of
the starting quantity of template cDNA. Consequently, the gene
dosage was deduced by calculating the difference in CT from the CT
of the reference gene glyceraldehyde-3-phosphate dehydrogenase.
The average CT values for target genes were subtracted from the
average housekeeping gene CT values to yield the DCT. Results were
finally expressed as 2DCT, which is an index of the relative amount
of gene expression.
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Histochemical staining and quantification
Paraffin-embedded methacarn-fixed sections were dewaxed with
xylene and stained with periodic acid-Schiff to evaluate FGS and IF.
FGS was scored semiquantitatively on a scale of 0–4 in 50 glomeruli
per kidney, FGS lesions were defined as glomerular areas with
mesangial expansion and adhesion formation simultaneously present
in one segment. The theoretical maximum score is 400. IF was scored
similarly in 30 interstitial fields. A score of 0 was given when no IF was
present in a field, 1 for 0–25% with IF, 2 for 25–50%, 3 for 50–75%,
and 4 for 75–100% of the field showing IF. IF was defined as expansion
of the interstitial space, with or without the presence of atrophied and
dilated tubules and thickened tubular basement membranes.
Immunohistochemistry and quantification
To assess the extent of tubular and interstitial injury in the different
groups, immunostaining for the following markers was performed:
a-SMA, a marker of pre-fibrotic changes, expressed by myofibro-
blasts (and in normal tissue in arteries) in the interstitial space
surrounding (injured) tubules (clone 1A4, Sigma, St Louis, MO,
USA); cIV, a marker of IF produced by fibroblasts and accumulating
in the interstitial space surrounding (injured) tubules (Southern
Biotech, Birmingham, AL, USA); OPN, a marker of tubular injury,
expressed in injured (proximal) tubular epithelial cells and in
normal kidneys in the medulla (clone MPIIIB10, Developmental
Hybridoma Studies, Iowa City, IA, USA); macrophages (ED1), an
antibody against monocytes and macrophages, thus a marker of
inflammation (ED1, Serotec, Oxford, UK); Kim-1, a novel marker of
tubular injury that is expressed at the apical membrane of injured
(proximal) tubular epithelial cells; peptide 9, a kind gift from Dr V
Bailly (Biogen Inc., Boston, MA, USA). After dewaxing and blocking
of endogenous peroxidase, incubation with the primary antibodies
was performed for 1 h at room temperature. Subsequently, sections
were incubated with appropriate secondary peroxidase-labelled
antibodies for 30 min. Peroxidase activity was developed using
3,30-diaminobenzidine tetrachloride for 10 min. Interstitial staining
of a-SMA, OPN, Kim-1, and cIV was measured by a blinded
observer using computerized image analysis (Advanced QUIPS,
Leica Imaging Systems, Cambridge, UK) in sections without
counterstaining. Fifty cortical sections per rat were scored with the
exclusion of glomeruli and blood vessels. Macrophages were
counted by a blinded observer in 50 interstitial fields per kidney.
Statistical analysis
Data were tested for normality and, when non-normal distribution
was present, differences between groups were detected by Kruskal–-
Wallis and Mann–Whitney U tests; otherwise, analysis of variance with
Bonferroni post hoc tests was used. We used analysis of variance to test
for linear trend. Spearman’s r correlation coefficients were calculated.
Linear regression was performed to calculate the association between
proteinuria, Kim-1, and OPN. Statistical analyses were performed
using SPSS version 12.0.2 and GraphPad Prism version 3.02. Data are
given as mean7standard deviation (s.d.), except for Figure 1, where
mean7standard error of the mean (s.e.m.) is given. Comparison of
blood pressure and proteinuria between the treatment groups was
performed for separate time points as well as for the mean of all values
obtained during treatment (weeks 7–18). Statistical significance was
assumed at the 5% level.
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